HK1100369A1 - Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof - Google Patents
Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereofInfo
- Publication number
- HK1100369A1 HK1100369A1 HK07107999.9A HK07107999A HK1100369A1 HK 1100369 A1 HK1100369 A1 HK 1100369A1 HK 07107999 A HK07107999 A HK 07107999A HK 1100369 A1 HK1100369 A1 HK 1100369A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- dpnag
- pnag
- poly
- methods
- binding peptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56410504P | 2004-04-21 | 2004-04-21 | |
PCT/US2005/013694 WO2005103084A2 (en) | 2004-04-21 | 2005-04-21 | Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1100369A1 true HK1100369A1 (en) | 2007-09-21 |
Family
ID=35197541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07107999.9A HK1100369A1 (en) | 2004-04-21 | 2007-07-24 | Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof |
Country Status (13)
Country | Link |
---|---|
US (13) | US7786255B2 (ja) |
EP (6) | EP2455401B1 (ja) |
JP (2) | JP5080243B2 (ja) |
CN (1) | CN101001874B (ja) |
AU (1) | AU2005236068C1 (ja) |
CA (1) | CA2567748A1 (ja) |
DK (1) | DK1745075T3 (ja) |
ES (2) | ES2415358T3 (ja) |
HK (1) | HK1100369A1 (ja) |
PL (1) | PL1745075T3 (ja) |
PT (1) | PT1745075E (ja) |
SI (1) | SI1745075T1 (ja) |
WO (1) | WO2005103084A2 (ja) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7252828B2 (en) | 1998-07-15 | 2007-08-07 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
US7047058B1 (en) | 2001-02-06 | 2006-05-16 | Medrad, Inc. | Apparatuses, systems and methods for extravasation detection |
EP1565478B1 (en) | 2002-11-12 | 2017-08-02 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
EP1583517B1 (en) | 2002-11-12 | 2019-06-12 | The Brigham And Women's Hospital, Inc. | Methods and products for treating staphylococcal infections |
DK1745075T3 (da) | 2004-04-21 | 2013-06-24 | Brigham & Womens Hospital | Poly-n-acetylglucosamin (pnag/dpnag)-bindende peptider og fremgangsmåder til anvendelse deraf |
HUE027099T2 (hu) * | 2006-06-06 | 2016-08-29 | Crucell Holland Bv | Humán kötõmolekulák staphylococcus elleni ölõaktivitással és alkalmazásuk |
AU2012268821B2 (en) * | 2006-06-06 | 2016-06-02 | Janssen Vaccines & Prevention B.V. | Human binding molecules having killing activity against staphylococci and uses thereof |
CA2654502C (en) | 2006-06-06 | 2015-07-14 | Crucell Holland B.V. | Human binding molecules having killing activity against enterococci and uses thereof |
US8455623B2 (en) | 2008-05-21 | 2013-06-04 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
DK2315747T3 (en) | 2008-07-21 | 2018-02-26 | Brigham & Womens Hospital Inc | Methods and Compositions of Synthetic Beta-1.6 Glucosamine Oligosaccharides |
CA2845259A1 (en) | 2011-08-15 | 2013-02-21 | The University Of Chicago | Compositions and methods related to antibodies to staphylococcal protein a |
WO2013033174A1 (en) | 2011-09-02 | 2013-03-07 | Battelle Memorial Institute | Extravasation and infiltration detection device |
WO2013075740A1 (en) | 2011-11-23 | 2013-05-30 | Sanofi | Antibody purification method |
JP2015517496A (ja) * | 2012-05-07 | 2015-06-22 | サノフイ | バイオフィルム形成を防止する方法 |
SG10201911609XA (en) * | 2012-05-30 | 2020-01-30 | Brigham & Womens Hospital Inc | Polysaccharide compositions and methods of use |
EP2888278A1 (en) * | 2012-08-24 | 2015-07-01 | Sanofi | Anti-poly-n-acetyl glucosamine (pnag) monoclonal antibody and uses thereof for the prevention or treatment of pnag expressing bacterial infection |
WO2014050518A1 (ja) | 2012-09-28 | 2014-04-03 | 日本電気株式会社 | 情報処理装置、情報処理方法および情報処理プログラム |
US9890216B2 (en) | 2012-10-23 | 2018-02-13 | Board Of Regents, The University Of Texas System | Antibodies with engineered IgG Fc domains |
WO2014142117A1 (ja) * | 2013-03-12 | 2014-09-18 | 全薬工業株式会社 | 抗ブドウ球菌抗体、その製造方法並びにその使用 |
BR112015027812B1 (pt) | 2013-05-06 | 2021-03-30 | Sanofi | Método para a purificação de uma proteína a partir de uma solução |
EP2889311B1 (en) * | 2013-12-30 | 2018-03-21 | Albert-Ludwigs-Universität Freiburg | Opsonic and protective monoclonal antibodies against gram-positive pathogens |
KR20190052006A (ko) | 2016-08-24 | 2019-05-15 | 테네오바이오, 인코포레이티드 | 변형된 중쇄-단독 항체를 생산하는 형질전환 비-인간 동물 |
WO2018204876A1 (en) * | 2017-05-04 | 2018-11-08 | City Of Hope | Antibody variable domains and antibody constructs |
WO2020167919A1 (en) | 2019-02-12 | 2020-08-20 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for using bispecific antibodies to bind complement and a target antigen |
CN110184231B (zh) * | 2019-05-31 | 2021-02-12 | 杭州丰海生物科技有限公司 | 一种胞外分泌pnag多糖的重组枯草芽孢杆菌及其应用 |
US11173199B2 (en) | 2019-11-13 | 2021-11-16 | Alopexx Inc. | Low contaminant compositions |
KR20220107001A (ko) * | 2019-11-22 | 2022-08-01 | 알로펙스, 인크. | Pnag 포함 미생물에 대한 연속 치료를 제공하는 방법 |
US10828360B1 (en) | 2020-02-04 | 2020-11-10 | OneBioPharma, Inc. | Methods for inhibiting biofilm formation |
WO2023173020A1 (en) * | 2022-03-11 | 2023-09-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody materials and methods targeting microbial polysaccharides |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US213668A (en) | 1879-03-25 | Improvement in ice-making apparatus | ||
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
JPS5452794A (en) | 1977-09-30 | 1979-04-25 | Kousaku Yoshida | Extracting of polysacchride from capusle containing epidermis staphylococus |
US4285936A (en) * | 1979-12-10 | 1981-08-25 | The United States Of America As Represented By The Secretary Of The Army | Method for producing a vaccine against bacterial infections caused by pseudomonas aeruginosa |
US4355023A (en) | 1980-09-30 | 1982-10-19 | The Massachusetts General Hospital | Antibody fragment compositions and process |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4443549A (en) * | 1981-10-19 | 1984-04-17 | Molecular Genetics, Inc. | Production of monoclonal antibodies against bacterial adhesins |
US4470925A (en) | 1982-05-05 | 1984-09-11 | E. I. Du Pont De Nemours And Company | Immunoglobulin half-molecules and process for producing hybrid antibodies |
US4462334A (en) | 1982-08-19 | 1984-07-31 | Kim Ho K | Solar animal structure |
US4465776A (en) * | 1982-09-27 | 1984-08-14 | Research Corporation | Monoclonal antibodies to vitamin B6 and immunoassay method |
US4652448A (en) * | 1982-10-07 | 1987-03-24 | Molecular Genetics, Inc. | Use of monoclonal antibodies against bacterial adhesins |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US4578458A (en) * | 1983-03-23 | 1986-03-25 | Brigham And Women's Hospital | Mucoid exopolysaccharide vaccine against Pseudomonas aeruginosa |
DK219084D0 (da) * | 1984-05-02 | 1984-05-02 | Frederik Carl Peter Lindberg | Antigen |
JPS6191131A (ja) * | 1984-10-09 | 1986-05-09 | Chugai Pharmaceut Co Ltd | 医薬品の吸着防止方法および組成物 |
GB8426463D0 (en) | 1984-10-19 | 1984-11-28 | Technology Licence Co Ltd | Monoclonal antibodies |
NZ214503A (en) * | 1984-12-20 | 1990-02-26 | Merck & Co Inc | Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates |
FR2581877B1 (fr) * | 1985-05-14 | 1987-12-18 | Louvain Universite Catholique | Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries |
US4786592A (en) * | 1986-06-18 | 1988-11-22 | Scripps Clinic And Research Foundation | Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin |
US5589591A (en) * | 1986-07-03 | 1996-12-31 | Advanced Magnetics, Inc. | Endotoxin-free polysaccharides |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
GB8621910D0 (en) | 1986-09-11 | 1986-10-15 | Technology Licence Co Ltd | Monoclonal antibodies |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
FR2619122B1 (fr) | 1987-08-03 | 1990-03-09 | Pasteur Institut | Procede d'obtention de polyosides capsulaires de staphylocoques, polyosides obtenus, applications de ces polyosides et souches pour la mise en oeuvre du procede |
US4859449A (en) * | 1987-09-14 | 1989-08-22 | Center For Molecular Medicine And Immunology | Modified antibodies for enhanced hepatocyte clearance |
CA1340506C (en) | 1987-11-24 | 1999-04-20 | Nicholas H. Carbonetti | Production of gonorrheal pi proteins and vaccines |
US5055455A (en) * | 1988-09-28 | 1991-10-08 | Brigham And Women's Hospital | Capsular polysaccharide adhesin antigen, preparation, purification and use |
US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
FR2640628A1 (fr) | 1988-12-16 | 1990-06-22 | Commissariat Energie Atomique | Oligosaccharides lies (beta)-(1 -> 6) en particulier des 2-acetamido-2-desoxy-glucoses ou - galactoses et leur preparation |
ATE120093T1 (de) | 1988-12-19 | 1995-04-15 | Praxis Biolog Inc | Meningococcales klasse i-aussenmembranprotein- vakzin. |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5571511A (en) * | 1990-10-22 | 1996-11-05 | The U.S. Government | Broadly reactive opsonic antibodies that react with common staphylococcal antigens |
DK0594743T3 (da) | 1991-07-12 | 1999-12-20 | Pfizer | Kontinuert cellelinje og vaccine mod aviær coccidia |
ES2198405T3 (es) | 1991-11-22 | 2004-02-01 | Nabi Biopharmaceuticals | Antigenos de superficie de tipo i asociados a staphylococcus epidermis. |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5872215A (en) * | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
EP0615458B1 (en) * | 1991-12-06 | 1997-08-06 | North Shore University Hospital Research Corporation | Method of reducing medical device related infections |
EP0635132B2 (en) | 1992-03-19 | 2008-05-14 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Broadly reactive opsonic antibodies that react with common staphylococcal antigens |
US5688516A (en) * | 1992-11-12 | 1997-11-18 | Board Of Regents, The University Of Texas System | Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices |
US5362754A (en) * | 1992-11-12 | 1994-11-08 | Univ. Of Tx Md Anderson Cancer Center | M-EDTA pharmaceutical preparations and uses thereof |
EP0680337A4 (en) | 1993-01-12 | 1997-07-30 | Anthony George Gristina | METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY. |
US5718694A (en) * | 1993-11-09 | 1998-02-17 | The Board Of Regents Of The University Of Nebraska | Inhibition of adherence of microorganisms to biomaterial surfaces by treatment with carbohydrates |
US5858350A (en) * | 1993-12-01 | 1999-01-12 | Marine Polymer Technologies | Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system |
WO1995024929A2 (en) | 1994-03-15 | 1995-09-21 | Brown University Research Foundation | Polymeric gene delivery system |
EP0699237B1 (en) * | 1994-03-17 | 2003-02-19 | MERCK PATENT GmbH | Anti-egfr single-chain fvs and anti-egfr antibodies |
US5945311A (en) | 1994-06-03 | 1999-08-31 | GSF--Forschungszentrumfur Umweltund Gesundheit | Method for producing heterologous bi-specific antibodies |
JPH0840932A (ja) | 1994-07-29 | 1996-02-13 | Kitasato Inst:The | スタフイロコッカス属菌感染症の予防ワクチン及び治療用抗体並びにそれの製造法 |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US5830539A (en) * | 1995-11-17 | 1998-11-03 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Methods for functionalizing and coating substrates and devices made according to the methods |
US6245735B1 (en) * | 1996-07-29 | 2001-06-12 | The Brigham And Women's Hospital, Inc. | Methods and products for treating pseudomonas infection |
DK0826696T3 (da) | 1996-09-03 | 2002-09-23 | Gsf Forschungszentrum Umwelt | Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet |
SK40599A3 (en) * | 1996-09-26 | 2000-06-12 | Chugai Pharmaceutical Co Ltd | Antibody against human parathormone related peptides |
US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
TW586934B (en) | 1997-05-19 | 2004-05-11 | Sumitomo Pharma | Immunopotentiating composition |
WO1999008705A1 (en) * | 1997-08-20 | 1999-02-25 | Brigham And Women's Hospital | Capsular polysaccharides from enterococci |
IT1298539B1 (it) | 1998-02-03 | 2000-01-12 | Bracco Spa | Metodo per la determinazione di infezioni da protesi |
EP1068312A2 (en) * | 1998-04-09 | 2001-01-17 | Genset | 5' ests and encoded human proteins |
AU4919699A (en) | 1998-07-11 | 2000-02-01 | Mhm Holdings Limited | Vehicle seat, vehicle seat table and vehicle communication system |
US7252828B2 (en) * | 1998-07-15 | 2007-08-07 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
WO2000003745A2 (en) * | 1998-07-15 | 2000-01-27 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
CA2356849C (en) | 1998-12-16 | 2008-06-03 | Sca Hygiene Products Zeist B.V. | Acidic superabsorbent polysaccharides |
WO2002094983A2 (en) | 2001-05-16 | 2002-11-28 | The Children's Hospital Of Philadelphia | Dna-antibody complexes to enhance gene transfer |
US6962813B2 (en) * | 2001-05-21 | 2005-11-08 | The Brigham And Women's Hospital, Inc. | P. aeruginosa mucoid exopolysaccharide specific binding peptides |
US7119172B2 (en) * | 2001-05-21 | 2006-10-10 | The Brigham And Women's Hospital, Inc. | P. aeruginosa mucoid exopolysaccharide specific binding peptides |
EP1461082A4 (en) | 2001-12-03 | 2006-06-28 | Abgenix Inc | ANTIBODIES AGAINST THE TUMOR ANTIGEN OF CARBON IX ANHYDRASE (CA IX) |
CA2469132A1 (en) | 2001-12-11 | 2003-07-03 | Merck & Co., Inc. | Staphylococcus aureus exopolysaccharide and process |
ATE364618T1 (de) * | 2001-12-28 | 2007-07-15 | Amgen Fremont Inc | Antikörper gegen das muc18-antigen |
US8420353B2 (en) | 2002-03-22 | 2013-04-16 | Aprogen, Inc. | Humanized antibody and process for preparing same |
WO2003085093A2 (en) * | 2002-04-01 | 2003-10-16 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
WO2004042407A1 (en) | 2002-11-04 | 2004-05-21 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 73a (gpr73a) |
EP1583517B1 (en) * | 2002-11-12 | 2019-06-12 | The Brigham And Women's Hospital, Inc. | Methods and products for treating staphylococcal infections |
EP1565478B1 (en) * | 2002-11-12 | 2017-08-02 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
DK1745075T3 (da) | 2004-04-21 | 2013-06-24 | Brigham & Womens Hospital | Poly-n-acetylglucosamin (pnag/dpnag)-bindende peptider og fremgangsmåder til anvendelse deraf |
US8510225B2 (en) | 2004-09-01 | 2013-08-13 | Research In Motion Limited | Split channel authenticity queries in multi-party dialog |
EP1844136B1 (en) | 2004-12-29 | 2014-08-27 | Hadasit Medical Research Services And Development Ltd. | Stem cells culture systems |
AR060188A1 (es) | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | Procedimiento de conjugacion |
DK2315747T3 (en) | 2008-07-21 | 2018-02-26 | Brigham & Womens Hospital Inc | Methods and Compositions of Synthetic Beta-1.6 Glucosamine Oligosaccharides |
AU2010216926B2 (en) | 2009-02-20 | 2014-02-27 | Meisho.Co.,Ltd | Immunopotentiating composition and process for producing same |
WO2012099805A2 (en) | 2011-01-19 | 2012-07-26 | Ocean Nanotech, Llc | Nanoparticle based immunological stimulation |
SG10201911609XA (en) | 2012-05-30 | 2020-01-30 | Brigham & Womens Hospital Inc | Polysaccharide compositions and methods of use |
EP3608416A1 (en) | 2013-01-22 | 2020-02-12 | Imicroq, S.L. | Rapid method for detection of pathogen |
-
2005
- 2005-04-21 DK DK05770709.3T patent/DK1745075T3/da active
- 2005-04-21 WO PCT/US2005/013694 patent/WO2005103084A2/en active Application Filing
- 2005-04-21 US US11/111,688 patent/US7786255B2/en active Active
- 2005-04-21 EP EP11185022.8A patent/EP2455401B1/en not_active Not-in-force
- 2005-04-21 EP EP11185027A patent/EP2455402A1/en not_active Withdrawn
- 2005-04-21 EP EP05770709A patent/EP1745075B1/en active Active
- 2005-04-21 EP EP11185020.2A patent/EP2455400B1/en active Active
- 2005-04-21 ES ES05770709T patent/ES2415358T3/es active Active
- 2005-04-21 JP JP2007509650A patent/JP5080243B2/ja not_active Expired - Fee Related
- 2005-04-21 ES ES11185020T patent/ES2738112T3/es active Active
- 2005-04-21 EP EP11185025.1A patent/EP2439213B1/en not_active Not-in-force
- 2005-04-21 PL PL05770709T patent/PL1745075T3/pl unknown
- 2005-04-21 CA CA002567748A patent/CA2567748A1/en not_active Abandoned
- 2005-04-21 EP EP11185030A patent/EP2468769A1/en not_active Withdrawn
- 2005-04-21 CN CN2005800203560A patent/CN101001874B/zh not_active Expired - Fee Related
- 2005-04-21 PT PT57707093T patent/PT1745075E/pt unknown
- 2005-04-21 AU AU2005236068A patent/AU2005236068C1/en not_active Ceased
- 2005-04-21 SI SI200531737T patent/SI1745075T1/sl unknown
-
2007
- 2007-07-24 HK HK07107999.9A patent/HK1100369A1/xx not_active IP Right Cessation
-
2010
- 2010-06-28 US US12/824,510 patent/US8084595B2/en not_active Expired - Fee Related
-
2011
- 2011-05-09 US US13/103,532 patent/US8252894B2/en active Active
- 2011-08-08 JP JP2011173372A patent/JP5717582B2/ja active Active
- 2011-12-22 US US13/334,807 patent/US8435515B2/en not_active Expired - Fee Related
- 2011-12-22 US US13/334,869 patent/US8410249B2/en not_active Expired - Fee Related
- 2011-12-22 US US13/334,775 patent/US8350017B2/en not_active Expired - Fee Related
- 2011-12-22 US US13/334,840 patent/US8461319B2/en not_active Expired - Fee Related
-
2013
- 2013-01-07 US US13/735,531 patent/US8912314B2/en not_active Expired - Fee Related
-
2014
- 2014-11-19 US US14/548,173 patent/US9458227B2/en active Active
-
2016
- 2016-09-20 US US15/270,461 patent/US10017563B2/en not_active Expired - Fee Related
-
2018
- 2018-06-11 US US16/005,647 patent/US10906962B2/en active Active
-
2020
- 2020-12-22 US US17/131,613 patent/US20210363228A1/en not_active Abandoned
-
2022
- 2022-08-17 US US17/820,406 patent/US20230382980A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1100369A1 (en) | Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof | |
EP1838331A4 (en) | ANTIMICROBIAL PEPTIDES AND METHODS OF USE THEREOF | |
GB2412589B (en) | Hyperbaric dressing | |
ZA200600716B (en) | Improvements in and to processes | |
IL190332A0 (en) | Human antibodies against il13 and therapeutic uses | |
HK1092315A1 (en) | Improvements in or relating to distributed radio units | |
IL179300A0 (en) | Novel-antigen-binding polypeptides and their uses | |
EP1757658A4 (en) | RUBBER COMPOSITION AND USE THEREOF | |
HK1097859A1 (en) | Anti-cd38 human antibodies and uses therefor -cd38 | |
ZA200703313B (en) | Recombinant human T2 RNase and uses thereof | |
EP1794589A4 (en) | PROTEIN ARRAYS AND METHOD OF USE THEREOF | |
IL178181A0 (en) | Fungicidal mixtures and novel triazolopyrimidines | |
EP1877344A4 (en) | BIOFILTER UNITS AND WATER TREATMENT PLANTS THEREWITH | |
EP1960523A4 (en) | MODIFIED POREN FORMING PROTEIN TOXINS AND USE THEREOF | |
TWI340752B (en) | Elastomer composition and molded body | |
EP1717272A4 (en) | POLYURETHANE COMPOSITION AND MOLDED ARTICLE MADE THEREFROM | |
GB0426161D0 (en) | Protein isolation and purification | |
SK50812005A3 (sk) | Zmesi polyuretánu a gumy | |
EP1931368A4 (en) | ANTIMYCOTIC PEPTIDES AND METHOD OF USE THEREOF | |
EP1687330A4 (en) | PEPTIDES WITH ANTIBODY EFFECT AND OTHER RELATED APPLICATIONS | |
GB0401182D0 (en) | Improvements in and relating to conveyors | |
EP1811985A4 (en) | NUTRIENT SUPPLEMENT AND USE OF SUCH SUPPLEMENT | |
EP1813671A4 (en) | SOLUBLE PROTEIN AND USE THEREOF | |
ZA200802541B (en) | Human antibodies against IL13 and therapeutic uses | |
EP1838728A4 (en) | HUMAN PROTOONKOGEN AND THE CODED PROTEIN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210415 |